TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: RICB (MNAP remaining after ischemia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative costs per patient at 5-year follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bleeding stopped after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrin clot formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer days of substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internalizing disorders prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Academic achievement scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in moderate incontinent episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCR (Creatinine Clearance Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients experiencing a flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of mild/moderate flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of change on English language outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of Spanish language skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in NCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VZV-specific CMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SF-36 role-physical scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Postoperative chest tube drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Use of homologous blood products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: achievement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage decrease in SCORAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IDQOL score decrease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DFI score decrease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Voluntary activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lower limb disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CD‐TLR rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean letters gained in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measured central retinal thickness (CRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity of BNP and NT-proBNP tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative Predictive Value (NPV) of BNP and NT-proBNP tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wound size decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral CD34+ EPCs average count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of seniors prescribed a potentially inappropriate medication (PIM)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean BMI at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained shifts in microbiomes associated with obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained decrease in stool levels of taurocholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-pass success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tube passage time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in NP size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-perceived benefit as measured by the APHAB
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: New organ dysfunction during the first 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioral and psychological symptoms of dementia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean IGF‐I sd score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean lean body mass increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gained 15 or more letters from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean central retinal thickness decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LF/HF ratio of R‐R intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: forced pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Crying hours
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sleep hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Colic severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of DWH
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in actinic keratosis (AK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of pigmentation and texture of field cancerized skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU-acquired severe sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: LDL-oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: antioxidant status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: observer-rated child anxiety at anesthetic induction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anesthesia induction compliance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of postoperative vomiting (POV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sum of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of confirmed first perceptible relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA level < 500 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT levels back to normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: innate immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean duration of the fasting migrating motor complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of activity fronts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of phase III contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean urinary leakage on a standard pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean urinary leakage on a 24‐h pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Muscle strength as measured by the Oxford scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe leukopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment interruptions or withdrawals due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percent seizure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete tablet disintegration time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in symptoms of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decrease in symptoms of drowsiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: decrease in symptoms of tiredness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: controlled and remarkably effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scores of symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of chronic postsurgical pain (CPSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of secondary mechanical hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: collagen aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rebound in viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body-shape abnormalities reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in the appearance of cellulite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum levels of inflammatory mediators (TNF-alpha, IL-6, MDA, SOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of organ function markers (AST, CK, CK-MB, BUN, Cr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complications (sepsis, multiple organ failure)
Endpoint domain: Adverse events/effects
Primary endpoint: Insertion time for cannula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure rates at first attempt
Endpoint domain: Adverse events/effects
Primary endpoint: Heart rate and HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eyelash growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UTDT positivity duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity of UTDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Specificity of UTDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: myocardial (re)infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: new congestive heart failure
Endpoint domain: Adverse events/effects
Primary endpoint: death/nonfatal myocardial infarction at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: MNC expression of IL‐1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MNC expression of CD68
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of LPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Appearance of carcinomatous pleuritis
Endpoint domain: Adverse events/effects
Primary endpoint: Impact on anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Engaging in regular exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Actively managing weight
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of positive pregnancy tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time needed for anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cost of anastomosis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: viral load <75 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in erythrocyte EPA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in erythrocyte DHA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: local failure rate
Endpoint domain: Mortality/survival
Primary endpoint: peak pursuit gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: catch-up saccade frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of flying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in distocervical inclinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct working diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soluble transferrin receptor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: vigor scores on the Profile of Mood States
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Airway inflammation prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma SDF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICH volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Incidence of Coronary Heart Disease (CHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of sprints during aRSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of grade 3 GU events
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative incidence of grade 3 GI events
Endpoint domain: Adverse events/effects
Primary endpoint: prevalence of erectile function at 5 years
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness of axillary vein approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of unsuccessful procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Days requiring invasive mechanical ventilation (IMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic requirement for respiratory infection
Endpoint domain: Adverse events/effects
Primary endpoint: Remission of anxious symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy on ADCS-IADL
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of subjects with gastric erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gingivitis
Endpoint domain: Adverse events/effects
Primary endpoint: Mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Candida albicans infection
Endpoint domain: Adverse events/effects
Primary endpoint: HCC surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 20-item Sino-Nasal Outcomes Test scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Salivary cortisol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increased moderate physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of self-injurious episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Borderline personality disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity (renal, auditive, neurologic)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean pain-free periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant pain relief (> or = 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of CNV closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean OCT central foveal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximum CIMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adipocyte leptin mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of treatment-emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proteinuria (g/24 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum albumin levels (g/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean arterial pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive testing timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal rating scale for pain scores >5
Endpoint domain: Adverse events/effects
Primary endpoint: Time to start out-of-bed activities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: venous active renin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: venous angiotensin II levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of FAAs and urea in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of bowel-cleansing procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyponatremia occurrence after bowel preparation
Endpoint domain: Adverse events/effects
Primary endpoint: Successful preparation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in hepatic fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intraoperative air leak cessation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Air leaks rate at 24h and 48h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative influence on daily life
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Culture conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HCQ concentrations in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: near best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spectacle independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the plasma concentration-time curves (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral clearance of reboxetine enantiomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean terminal half-life after administration of ketoconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of PFAPA attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of modern contraceptives for spacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time period from drug administration to full dilation of the cervix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dilatation of cervix between 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healthy dietary behavior change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder flexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: abduction range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Microvascular endothelial function deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Circulating ET-1 concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean intimal area increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Chronic nonspecific low back pain syndrome intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct execution of vertical lifting techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correct execution of horizontal patient lifting techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes